# Roll-over Study to Allow Continued Access to Ribociclib

> **NCT05161195** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 134 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Goserelin
- **DRUG:** Tamoxifen
- **DRUG:** Fulvestrant

## Key facts

- **NCT ID:** NCT05161195
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-07
- **Primary completion:** 2030-06-28
- **Final completion:** 2030-08-14
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05161195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05161195, "Roll-over Study to Allow Continued Access to Ribociclib". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05161195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*